Results 311 to 320 of about 1,395,710 (388)

Combating cancer immunotherapy resistance: a nano‐medicine perspective

open access: yesCancer Communications, EarlyView.
Abstract Cancer immunotherapy offers renewed hope for treating this disease. However, cancer cells possess inherent mechanisms that enable them to circumvent each stage of the immune cycle, thereby evading anti‐cancer immunity and leading to resistance.
Xiangyi Kong   +10 more
wiley   +1 more source

Galectin-9 treatment is cytotoxic for B cell lymphoma by disrupting autophagy. [PDF]

open access: yesFront Pharmacol
Koll L   +7 more
europepmc   +1 more source

Neutrophils in cancer: At the crucial crossroads of anti‐tumor and pro‐tumor

open access: yesCancer Communications, EarlyView.
Abstract Neutrophils are important components of the immune system and play a key role in defending against pathogenic infections and responding to inflammatory cues, including cancer. Their dysregulation indicates potential disease risk factors. However, their functional importance in disease progression has often been underestimated due to their ...
Wenpeng Cai   +6 more
wiley   +1 more source

Primary Breast Lymphoma: A Rare Presentation of Diffuse Large B-Cell Lymphoma, Germinal Center B-Cell Subtype (DLBCL-GCB). [PDF]

open access: yesCureus
Chrysikos D   +7 more
europepmc   +1 more source

Burkitt lymphoma in Papua, New Guinea.

open access: green, 1967
Kathryn Booth   +4 more
openalex   +2 more sources

Extranodal diffuse large B‐cell lymphoma: Clinical and molecular insights with survival outcomes from the multicenter EXPECT study

open access: yesCancer Communications, EarlyView.
Abstract Background Diffuse large B‐cell lymphoma (DLBCL) is the most common subtype of aggressive non‐Hodgkin's lymphoma with distinct clinical and molecular heterogeneity. DLBCL that arises in extranodal organs is particularly linked to poor prognosis. This study aimed to determine the clinical and molecular characteristics of extranodal involvement (
Si‐Yuan Chen   +46 more
wiley   +1 more source

Home - About - Disclaimer - Privacy